RT Journal Article
T1 Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review
A1 Buzón Martín, Luis
A1 Zollner Schwetz, Ines
A1 Tobudic, Selma
A1 Cercenado Mansilla, Emilia
A1 Lora-Tamayo Morillo-Velarde, Jaime
AB Dalbavancin (DAL) is a lipoglycopeptide with bactericidal activity against a very wide range of Gram-positive microorganisms. It also has unique pharmacokinetic properties, namely a prolonged half-life (around 181 h), which allows a convenient weekly dosing regimen, and good diffusion in bone tissue. These features have led to off-label use of dalbavancin in the setting of bone and joint infection, including prosthetic joint infections (PJI). In this narrative review, we go over the pharmacokinetic and pharmacodynamic characteristics of DAL, along with published in vitro and in vivo experimental models evaluating its activity against biofilm-embedded bacteria. We also examine published experience of osteoarticular infection with special attention to DAL and PJI.
PB MPDI
SN 2079-6382
YR 2021
FD 2021-05-31
LK https://hdl.handle.net/20.500.14352/7124
UL https://hdl.handle.net/20.500.14352/7124
LA eng
NO Buzón-Martín L, Zollner-Schwetz I, Tobudic S, Cercenado E, Lora-Tamayo J. Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review. Antibiotics 2021;10:656. https://doi.org/10.3390/antibiotics10060656.
DS Docta Complutense
RD 7 abr 2025